MGX · Metagenomi Therapeutics, Inc.
Market Cap
$30.67M
Shares
37.78M
Volume · Oct 20
20.45K
Avg daily vol (3M)
157.61K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.81
Open$0.80
Day$0.80–0.84
52W close$0.78–3.35
Avg vol 30d175K
Short int1.3M · 3.4% float · 10.5d
Short vol45%
Last earningsNov 12, 2025
DataFeb 2024–Oct 2026
Filing10-Q · Aug 10
Up next
filed Aug 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$22.33M
Trailing 12 months
Net income (TTM)
−$93.46M
Trailing 12 months
Revenue growth YoY
-69.8%
Year over year
Operating margin
-380.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-289.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$39.03M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.3%
Year over year · more shares
Price change (1Y)
-73.4%
Trailing year
Short interest
3.4%
Latest settlement · 10.5 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−39%
below
Price vs 50-day avg
−27%
below
RSI (14)
25
oversold
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−28%
trailing
6-month return
−44%
trailing
YTD return
−50%
this year
Relative strength
−51%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
2 of 43 funds reported for Sep 30 · net -72.0K sh shares
Insider flow
Accumulating
Net +$18.3K over 90 days · 75% sells
Short interest
Falling
3.37% of float · ▼ -11.1% MoM · 10.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
43 holders — near 2-yr low, contrarian setup
Squeeze score
54
elevated · 0–100
Fundamentals
Revenue growth
−52%
Y/Y
EPS growth
0%
Y/Y
Free cash flow
$-89.5M
Balance sheet
$41.7M
net cash
Quant / Vol
risk profile
Volatility
57%
annualized · 1-yr
Max drawdown
−77%
past year
ATR
7.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−39%
Bearish
Price vs 50-day avg
−27%
Bearish
RSI (14)
25
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
2 of 43 funds reported for Sep 30 · net -72.0K sh shares
Insider flow
Accumulating
Net +$18.3K over 90 days · 75% sells
Short interest
Falling
3.37% of float · ▼ -11.1% MoM · 10.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
43 holders — near 2-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $1 · 1%
Range high $3
vs 200-day avg -39%
vs 50-day avg -27%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| reduction in organizational headcount | 25% | quarter ended December 31, 2025 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MGX
this stock
Metagenomi Therapeutics, Inc.
|
$30.67M | -49.9% | -51.8% | — | 3.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MGX | -20.4% | -27.5% | -43.6% | -23.4% | -49.9% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -18.9% | -26.6% | -51.3% | -23.9% | -62.3% |